News

This review of the latest dermatological studies includes insights on lichen planus in family members, "washcloth withdrawal," the use of shiitake mushroom extract in dermatology, and more.

The consensus summarizes contemporary real-world data showing that nearly 1 in 5 adolescents and adults with atopic dermatitis receive systemic corticosteroids.

FDA eases iPLEDGE REMS for isotretinoin acne care, allowing some at-home pregnancy tests and fewer lockouts to reduce administrative burden.

Septerna to share phase 1 SEP-631 results at AAAAI, targeting MRGPRX2 to curb mast cell flares and broaden options for refractory CSU.

Catch up on the health and dermatology-related commercials that aired during the 2026 Super Bowl.

REZOLVE-AD shows rezpegaldesleukin delivers durable atopic dermatitis control with monthly or quarterly dosing, supporting Nektar’s phase 3 plans.

Review identifies clinical and lab predictors of early antihistamines CSU and omalizumab CSU response, guiding personalized treatment.

A new molecular test offers clinicians a way to personalize treatment for moderate to severe atopic dermatitis and reduce therapeutic cycling, helping to achieve faster control and a better experience for patients.

Todd Schlesinger, MD, discusses emerging evidence, clearance outcomes, and practical considerations for using red light–based photodynamic therapy as a nonsurgical option in select superficial basal cell carcinoma (BCC) cases.

In omalizumab-resistant chronic spontaneous urticaria (CSU), tofacitinib rapidly calmed symptoms, but relapses varied.

Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.

Takeda’s recent announcement of positive top-line phase 3 results for zasocitinib (TAK-279) places this investigational agent squarely within that evolving conversation.

Bispecific and trispecific biologics are being developed to achieve deeper clearance and more meaningful symptom relief.

Modern hidradenitis suppurativa (HS) management prioritizes restoration of function and quality of life, not just reduction in lesion counts, according to Barry Resnik, MD.

Clinicians are increasingly facing barriers when attempting to prescribe on-label treatments for indicated patients.

Catch up on coverage from the third day of South Beach Symposium 2026.

GLP-1 therapies represent a paradigm shift requiring dermatology to integrate metabolic, medical, and aesthetic care.

At South Beach Symposium 2026, Mona Shahriari explores OX40/OX40L therapies for atopic dermatitis.

Glynis Ablon, MD, FAAD, examines the intersection of menopause, hormones, and dermatologic health.

At MOPD 2026, Lisa Swanson, MD, urges fungal cultures amid terbinafine resistance and warns attendees about risky kids’ skin care trends.

At South Beach Symposium 2026, Benjamin Ungar, MD, discussed safer, long-term approaches for seborrheic dermatitis.

Catch up on coverage from the second day of South Beach Symposium 2026.

Glynis Ablon, MD, FAAD, shares insights on diagnosing alopecia fast, managing aesthetic complications, and choosing evidence-based supplements.

Antonio Torrelo, MD, emphasizes that genetic testing enhances—but never replaces—clinical judgment in pediatric dermatology.

Doris Day, MD, reframes anti-aging: support fibroblasts, longevity pathways, lifestyle and smart fillers for healthier skin quality.

At SBS 2026, Karan Lal, MD, and Mohammad Goldust, MD, reveal how social media and AI reshape dermatology trust and care.

Phase 2 BEACON study shows brepocitinib rapidly clears cutaneous sarcoidosis lesions with strong CSAMI gains and tolerability, as Priovant readies phase 3 program.

David Cotter, MD, PhD, underscored the importance of incorporating quality-of-life and mental health measures into psoriasis clinical trials.

Catch up on coverage from the first day of South Beach Symposium 2026.

At MOPD 2026, Nanette Silverberg, MD, and Lisa Swanson, MD, unpack teen AD, fragrance allergy, and social media skin care hype harming barriers.